LTFS
CLRB icon

Ladenburg Thalmann Financial Services’s Cellectar Biosciences CLRB Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$10K Sell
13
-17
-57% -$8.84K ﹤0.01% 4475
2019
Q3 		$18K Buy
30
+17
+131% +$11.1K ﹤0.01% 4097
2019
Q2 		$9K Buy
13
+7
+117% +$4.77K ﹤0.01% 4477
2019
Q1 		$5K Hold
6
– – ﹤0.01% 4641
2018
Q4 		$3K Buy
+6
New +$4.27K ﹤0.01% 4746
2017
Q1 		– Hold
0
– – – 4851
2016
Q4 		– Hold
0
– – – 4854
2016
Q3 		– Hold
0
– – – 4602

Other funds holding CLRB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GPFA
Game Plan Financial Advisors Westlake, Ohio $222M AUM 22.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Ladenburg Thalmann Financial Services's CLRB Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services reduced its Cellectar Biosciences (CLRB) stake by 57% in Q4 2019, selling an estimated $8.84K and leaving 13 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #4475.

Ladenburg Thalmann Financial Services first reported a position in CLRB in Q4 2018 and has held it in 5 quarters since. The position peaked at $18K in Q3 2019. 10 funds tracked by Wall St. Rank hold CLRB as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 13 shares of Cellectar Biosciences worth $10K as of Q4 2019.
  • Ladenburg Thalmann Financial Services sold 17 Cellectar Biosciences shares in Q4 2019, an estimated $8.84K.
  • Cellectar Biosciences made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #4475 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Cellectar Biosciences in Q4 2018 and has held it in 5 quarters since.
  • Ladenburg Thalmann Financial Services's Cellectar Biosciences position peaked at $18K in Q3 2019.
  • 10 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.